The fully self-contained laboratory tablet coating machine requires only power and compressed air to operate.
All contact parts are in 316L stainless steel, or US FDA approved materials.
The unit can be used for the development of coating processes, and also for marketing and colour matching.
The system uses a 5.7in colour touchscreen to control all operations. Heat recovery is available from all heat sources reducing energy requirements and exhaust air temperature.
Batch sizes for drum coating are from 4kg down to 400g, but there is an option to convert the system to a Wurster Column and coat batches down to 40g.
Maintenance is kept to a minimum with quick-release operator parts and push-in connectors that eliminate the need for special tools. Rapid strip down and re-assembly saves time between batches and all parts can be cleaned ultrasonically.
Tablet coating machine for small batches
The CSI Technicota LAB coats batches down to 40g when converted to a Wurster Column
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Read morePrecise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing]()
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![From speed to strategy: how UK life sciences should respond to China’s rise]()
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?
